Thereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 015389-002950US Client Reference No.: 18/206P2

Commissioner for Patents

Box 1450

Alexandria, VA 22313-1450

on Oct. 6,2003

TOWNSEND and TOWNSEND and CREW LLP

Nicole M. Wartell

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

CECH et al.

Application No.: 08/974,584

Filed: November 19, 1997

For: TELOMERASE REVERSE

TRANSCRIPTASE

Examiner: Myers, Carla J.

Art Unit: 1634

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37

CFR §1.97 and §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

18/89/2883 NROCHAI 88888818 281438 889745

01 FC:1886

188.66 DA

CECH et al. PATENT

Application No.: 08/974,584

Page 2

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Scott L. Ausenhus Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8<sup>th</sup> Floor San Francisco, California 94111-3834

Tel: 303-571-4000 Fax: 303-571-4321

SLA:nmb

60038006 v1

Substitute for form 1449A/PTO

MFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of | 5

	•	
	Complete if Known	
Application Number	08/974,584	
Filing Date	November 19, 1997	
First Named Inventor		
Art Unit	1634	
Examiner Name	Myers, Carla J.	
Attorney Docket Number	015389-002950US	

			U.S. PATENT DO	CUMENTS+	
		Document Number	·		
Examiner Initials*	Cite No.1	Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	U\$-5,597,697	01-28-1997	Diamond	
	A2	US-5,747,317	05-05-1998	Cao	
	А3	US-5,770,422	06-23-1998	Collins	
	A4	US-5,917,025	06-29-1999	Collins	
	A5	US-5,919,656	07-06-1999	Harrington, et al.	
	A6	US-6,166,178	12-26-2000	Cech et al.	
	A7	US-6,337,200 B1	01-08-2002	Morin	
	A8	US-6,475,789 B1	11-05-2002	Cech et al.	
	A9	US-6,610,839 B1	08-26-2003	Cech et al.	
	A10	US-6,617,110 B1	09-09-2003	Cech et al.	

			FOREIGN	PATENT DOCUME	NTS	<del></del>	-
Examiner	Cite	Foreign Patent Document		Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Initials*	No. <sup>1</sup>	Country Code <sup>3</sup>	Number <sup>4</sup> Kind Code <sup>5</sup> (if know	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T⁵
	B1	GB	2 317 891 / A	04-08-1998			
	B2	PCT	WO 93/23572 / A1	11-25-1993			
	B3	PCT	WO 94/17210 / A1	08-04-1994			
	B4	PCT	WO 95/13382 / A1	05-18-1995			
	B5	PCT	WO 96/01835 / A1	01-25-1996			
	B6	PCT	WO 98/07838 / A1	02-26-1998		see abstract	
	B7	PCT	WO 98/08938 / A1	03-05-1998		see abstract	
	B8	PCT	WO 98/14592 A2	04-09-1998			
	B9	РСТ	WO 98/14593 / A2	04-09-1998			
	B10	PCT	WO 98/21343 / A1	05-22-1998			
	B11	PCT	WO 98/23759 / A2	06-04-1998			
	B12	PCT	WO 98/37181 ./ A2	08-27-1998			
	B13	PCT	WO 98/45450 / A1	10-15-1998			
	B14	PCT	WO 98/59040 ./ A2	12-30-1998			
	B15	PCT	WO 99/01560 / A1	01-14-1999			
	B16	PCT	WO 99/33998 - A2	07-08-1999			
	B17	PCT	WO 99/38964 A2	08-05-1999			
	B18	PCT	WO 00/46355 A2	08-10-2000			

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 

Applicant's unique citation designation number (optional). 

Kind Codes of U.S. Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 

Applicant is to be appropriate symbols as the head. place a check mark here if English language Translation is attached. 60038006 ∨1

Sheet

Superjute for form 1449B/PTO

2

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of 5

(use as many sheets as necessary)

Complete if Known Application Number 08/974,584 Filing Date November 19, 1997 First Named Inventor Art Unit 1634 Examiner Name Myers, Carla J. 015389-002950US Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	C1	ADAMSON, D. et al. "Significant Telomere Shortening in Childhood Leukemia", Cancer Genet. Cytogenet, 1992; pp. 204-206, Vol. 61	
	C2	AUTEXIER, CHANTAL, et al., "Telomerase and cancer: revisiting the telomere hypothesis; Trends in Biochemical Sciences, 1996, pp. 387-391, Vol. 10, No. 21.	
	СЗ	AVILION, A., "Characterization and expression of human telomerase," Dissertation Abstracts International", 1996, pp. 5930-B, Vol. 56, No. 11	
	C4	BARINGA, MARCIA, "The Telomerase Picture Fills In", Science, April 25, 1997; pp. 528-529, Vol. 276	,
	C5	CHIU, et al. "Replicative senescence and cell immortality: the role of telomeres and telomerase (44075)", <i>Proc. Soc. Exp. Bio. Med.</i> , 1997, pp. 99-106, Vol. 214.	
	C6	CHONG, L. et al. "A Human Telomeric Protein", Science, Dec. 1995, pp. 1663-1667, Vol. 270.	
	C7	COLLINS, KATHLEEN, "Structure and function of telomerase", Current Opinion in Cell Biology, 1996, pp. 374-380, Vol. 8	
	C8	COUNTER, C. et al. "Telomerase activity in human ovarian carcinoma"; <i>Proc. Natl. Acad. Sci USA;</i> April 1994; Vol. 91; pp. 2900-2904 ~	
	C9	COUNTER, C. et al. "Telomerase Activity in Normal Leukocytes and in Hematologic Malignancies" Blood; May 1, 1995; pp. 2315-2320, Vol. 85; No. 9.	
	C10	COUNTER, C. et al. "Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity", <i>The EMBO Journal</i> ; 1992, pp. 1921-1929, Vol. 11; No. 5, Oxford University Press.	
	C11	DE LANGE, T. et al. "Structure and Variability of Human Chromosome Ends"; <i>Molecular and Cellular Biology;</i> February 1990; pp. 518-527, Vol. 10, No. 2.	
	C12	FENG et al., "The RNA Componant of Human Telomerase," Science, 1995, pp. 1236-1241, Vol. 269	
	C13	FLAVELL, R. & MATHIAS, R. "Prospects for transforming monocot crop plants", <i>Nature</i> , 12 Jan. 1984, pp. 108-109, Vol. 307.	
	C14	FRESHNEY, <u>Culture of Animal Cells, A Manual Basic Technique</u> , p. 4, Alan R. Liss, Inc. New York, 1983.	
	C15	Genbank Accession No. A46242; September 21, 1993	
	C16	Genbank Accession No. AA299878; April 18, 1997	

Examiner	Date	
LXailillei	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO MFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)

3

Sheet

of 5

Complete if Known				
Application Number	08/974,584			
Filing Date	November 19, 1997			
First Named Inventor				
Art Unit	1634			
Examiner Name	Myers, Carla J.			
Attorney Docket Number	015389-002950US			

***	T	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner Initials *	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т:
	C17	Genbank Accession No. AA311750; April 19, 1997	
	C18	Genbank Accession No. L38903; January 30, 1995	
	C19	Genbank Accession No. Q06163; November 01, 1995	
	C20	Genbank Accession No. S39696; October 07, 1994	
	C21	Genbank Accession No. S53396; May 5, 1995	
	C22	GenBank Accession No. W70315; June 19, 1996	
	C23	GLASER, P. et al. "Bacillus subtilis genome project: cloning and sequencing of the 97 kb region from 325° to 333°" <i>Molecular Microbiology</i> , 1993, pp. 371-384, Vol. 10, No. 2.	
	C24	GOODMAN, R. et al. "Gene Transfer in Crop Improvement", Science, 3 April 1997, pp. 48-54, Vol. 236.	
	C25	GREIDER, C. "Telomeres, Telomerase and Senescence"; <i>BioEssays</i> ; 1990; pp. 363-369, Vol. 12, No. 8.	/
	C26	HARLEY, C. "Telomere loss: Mitotic clock or genetic time bomb?" <i>Mutation Research</i> ; 1991; pp. 271-282, Vol. 256, Elsevier Science Publishers.	
	C27	HARLEY, C. & VILLEPONTEAU, B. "Telomeres and telomerase in aging and cancer" Current Opinion in Genetics and Development; 1995, pp. 249-255, Vol. 5.	
	C28	HARLEY, C. et al. "Telomeres shorten during ageing of human fibroblasts", <i>Nature</i> , 31 May 1990; pp. 458-460, Vol. 345.	
	C29	HASTIE, N. et al. "Telomere reduction in human colorectal carcinoma and with ageing", <i>Nature</i> , 30 August 1990, pp. 866-868, Vol. 346.	
	C30	HEALY, K. C. "Telomere dynamics and telomerase activation in tumor progression: prospects for prognosis and therapy" <i>Oncol. Res.</i> , 1995, pp. 121-130, Vol. 7	
	C31	HENDERSON, C. Cancer genetics gene regulates telomerase resulting in death of cancer cells; Gene Therapy Weekly, 11 September 1995.	
	C32	HIYAMA, E. et. al. "Correlating telomerase activity levels with human neuroblastoma outcomes"; Nature Medicine; 3 March 1995; pp. 249-255, Vol. 1, No. 3.	
	C33	HOLTZMANN, K. et al. "Telomeric Associations and Loss of Telomeric DNA Repeats in Renal Tumors", Genes, Chromosomes & Cancer, 1993, pp. 178-181, Vol. 6.	

		•
Examiner	Date	
Signature	Considered	
Oignature	0010100	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

ute for form 1449B/PTO

## TNFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

4 of 5 Sheet

Complete if Known				
Application Number	08/974,584			
Filing Date	November 19, 1997			
First Named Inventor				
Art Unit	1634			
Examiner Name	Myers, Carla J.			
Attorney Docket Number	015389-002950US			

	1	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	T
Examiner Initials *	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	C34	JÄHNE, A. et al. "Genetic Engineering of Cereal Crop Plants: A Review", Euphytica, 1995, pp. 35-44, Vol. 85, Kluwer Academic Publishers, Netherlands.	
	C35	JOHNSON, P. et al., "Expression of Wild-Type p53 Is Not Compatible with Continued Growth of p53-Negative Tumor Cells", <i>Molecular and Cellular Biology</i> , Jan. 1991, p. 1-11, Vol. 11, No. 1.	
	C36	JOLLIFFE, L.K. "Humanized antibodies: enhancing therapeutic utility through antibody engineering", Int. Rev. Immunol., 1993, pp. 241-250, Vol. 10	
	C37	KIM, N. et al. "Specific Association of Human Telomerase Activity with Immortal Cells and Cancer", <i>Science</i> , 23 December 1994, pp. 2011-2014, Vol. 266.	
	C38	KLINGELHUTZ, A. et al. "Restoration of Telomeres in Human Papillomavirus- Immortalized Human Anogenital Epithelial Cells"; <i>Molecular and Cellular Biology</i> ; Feb. 1994, pp. 961-969, Vol. 14, No. 2.	
	C39	LEWIS, A. & CROWE, J.S. "Generation of humanized monoclonal antibodies by 'best fit' framework selection and recombinant polymerase chain reaction", <i>Year Immunol.</i> , 1993, pp. 110-118, Vol. 7	
	C40	Linking telomerase and tumors; <i>Genesis Report- Dx</i> ; 1995; Vol. 4, No. 6; Publisher Genesis Group Associates.	
	C41	LUNDBLAD, V. & BLACKBURN, E., Letter to the Editor entitled, "RNA-Dependent Polymerase Motifs in EST1: Tentative Identification of a Protein Component of an Essential Yeast Telomerase", <i>Cell</i> , 23 Feb. 1990, pp. 529-530, Vol. 60.	
	C42	LUSTIG, ARTHUR J., "The identification of telomerase subunits: catalysing telomere research", Trends in Cell Biology; August 1997, pp. 299-302, Vol. 7.	
	C43	MALICKI, J. et al. "A human HOX4B regulatory element provides head-specific expression in Drosophila embryos", Nature, 23 July 1992, pp. 345-357, Vol. 358.	
	C44	NAKAYAMA, J. et al. "Cloning of a Candidate cDNA Encoding a Proteinaceous Component of Mammalian Telomerase", <i>Molecular Biology Cell Abstracts Supp.</i> 7, 1996, p. 875-884, 286a Section 1664.	
	C45	NATARAJAN et al. "Major histocompatibility complex determinants select T-cell receptor alpha chain variable region dominance in a peptide-specific response." <i>Proc. Natl. Acad. Sci.</i> , Oct 1992, pp. 8874-8878, Vol. 19.	
	C46	PASZKOWSKI, JERZY et al. "Direct gene transfer to plants," The EMBO Journal, 1984, pp. 2717-2722, Vol. 3, No. 12.	
	C47	POTRYKUS, I. et al. "Direct gene transfer to cells of a graminaceous monocot", <i>Mol. Gen. Genet.</i> , 1985, pp. 183-188, Vol. 199.	
	C48	RAYMOND, E., et al.; Agents that target telomerase and telomeres; <i>Curr. Opin. Biotechnol.</i> ; 1996; 7:583-91	

Examiner	Date	·············
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

ute for form 1449B/PTO **FORMATION DISCLOSURE** STATEMENT BY APPLICANT (use as many sheets as necessary)

of 5

5

Sheet

Complete if Known					
Application Number	08/974,584				
Filing Date	November 19, 1997				
First Named Inventor					
Art Unit	1634				
Examiner Name	Myers, Carla J.				
Attorney Docket Number	015389-002950US				

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C49	RHYU, M.S. "Telomeres, telomerase, and immortality"; <i>J. Natl. Cancer Inst.</i> ; 21 June 1995; pp. 884-894, Vol. 87, No. 12.	
	C50	SCHENA et al. "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes", <i>Proc. Natl. Acad. Sci.</i> , Oct. 1996, pp. 10614-10619, Vol. 93, USA.	
	C51	SCHWARTZ, H. et al. "Telomere Reduction in Giant Cell Tumor of Bone and with Aging"; Cancer Genet Cytogenet; 1993; pp. 132-138, Vol. 71, Elsevier Science Publishing Co., Inc., New York, U.S.A,	
	C52	SINGER, M. "Unusual Reverse Transcriptases", Journal of Biological Chemistry; 1995, pp. 24623-23626, Vol. 270, No. 42	
	C53	SMITH, J. & YEH, G. "Telomere Reduction in Endometrial Adenocarcinoma"; <i>Am. J. Obstet. Gynecol.</i> ; Dec. 1992; pp. 1883-1887, Vol. 167, No. 6	
	C54	TAIT, J. et al. "Structure and Polymorphisms of the Human Annexin III (ANX3) Gene", <i>Genomics</i> , 1993, pp. 79-86, Vol. 18, No. 1	
	C55	WINTER, G. & HARRIS, W. "Humanized Antibodies", <i>Trends Pharmacol. Sci.</i> , May 1993, pp. 139-143, Vol. 14.	
	C56	WIRTH, URS et al; "Immediate-Early RNA 2.9 and Early RNA 2.6 of Bovine Herpesvirus 1 Are 3' Coterminal and Encode of Putative Zinc Finger Transactivator Protein"; <i>Journal of Virology</i> ; May 1992; pp. 2763-2772, Vol. 66, No. 5.	
	C57	ZAUG, ARTHUR et al., "Method for determining RNA 3' ends and application to human telomerase RNA", <i>Nucleic Acids Research</i> , 1996, pp. 532-533, Vol. 24, No. 3.	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/17 (08-03)

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL	ABSOLIBIT	^-	CAMBELL
IUIAL	AMOUNI	Ur	PAYMENT

180

	Complete if Known	
Application Number	08/974,584	
Filing Date	November 19, 1997	-
First Named Inventor	Cech, Thomas	
Examiner Name	1634	
Art Unit	Myers, Carla J.	
Attorney Docket No.	015389-002950US	

				<u> </u>		
METHOD OF PAYMENT (check all that apply)	1 155	TION	CEEC	FEE C	ALCULATION (continued)	
Check Credit Card Money Order Other None		ITIONAL	1			
Deposit Account:	Large Fee	Entity Fee	Small Fee	Entity Fee		Fee
Deposit Account 20-1430	Code	(\$)	Code	(\$)	Fee Description	Paid
Account 20-1430 Number	1051	130	2051	65	Surcharge - late filing fee or oath	
	1052	50	2052	25	Surcharge - late provisional filing fee	
Deposit	4050	100		400	or cover sheet.	
Account Townsend and Townsend and Crew LLP Name	1053	130	1053	130	Non-English specification	
	1812 1804	2,520 920*	1812 1804	2,520 920*	For filing a request for reexamination	
The Director is authorized to: (check all that apply)  Charge fee(s) indicated below  Credit any overpayments	1004	920	1004	920	Requesting publication of SIR prior to Examiner action	
Charge any additional fee(s) during the pendency of this application	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
Charge fee(s) indicated below, except for the filing fee	1251	110	2251	55	Extension for reply within first month	
to the above-identified deposit account.	1252	410	2252	205	Extension for reply within second	
FEE CALCULATION	1				month	
1. BASIC FILING FEE	1253	930	2253	465	Extension for reply within third month	
Large Entity Small Entity	1254	1,450	2254	725	Extension for reply within fourth month	
Fee Fee Fee Fee Description Fee Paid	1255	1,970	2255	985	Extension for reply within fifth month	
Code (\$)   Code (\$)	1401	320	2401	160	Notice of Appeal	
1001 750 2001 375 Utility filing fee	1402	320	2402	160	Filing a brief in support of an appeal	
1002 330 2002 165 Design filing fee	1403	280	2403	140	Request for oral hearing	
1003         520         2003         260         Plant filing fee           1004         750         2004         375         Reissue filing fee	1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1005 160 2005 80 Provisional filing fee	1452	110	2452	55	Petition to revive - unavoidable	
	1453	1,300	2453	650	Petition to revive – unintentional	
SUBTOTAL (1) (\$)	1501	1,300	2501	650	Utility issue fee (or reissue)	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1502	470	2502	235	Design issue fee	
	1503	630	2503	315	Plant issue fee	
Fees from Extra Claims below Fee Paid	1460	130	1460	130	Petitions to the Commissioner	
Total Claims -** = X =	1807	50	1807	50	Petitions related to provisional applications	
Independent Claims -** =	1806	180	1806	180	Submission of Information Disclosure Stmt	180
Multiple Dependent	8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
Large Entity Small Entity Fee Fee Fee Fee For Broading	1809	750	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
Code (\$) Fee Description  1202 18 2202 9 Claims in excess of 20	1810	750	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1201 84 2201 42 Independent claims in excess of 3	1801	750	2801	375	Request for Continued Examination (RCE)	
1203 280 2203 140 Multiple dependent claim, if not paid	1802	900	1802	900	Request for expedited examination	
1204 84 2204 42 Reissue independent claims over original patent					of a design application	
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent	Other fe	ee (specify	/)		···	
SUBTOTAL (2) (\$)	*Reduc	ed by Bas	ic Filing	Fee Pa	id SUBTOTAL (3) (\$)180	
**or number previously paid, if greater; For Reissues, see above		•			` '	
	L					

SUBMITTED BY		c	Complete (if applicable)			
Name (Print/Type)	Scott L. Ausenhus	Registration No. (Attorney/Agent)	42,271	Telephone	303-571-4000	
Signature	sot lu	Menday		Date		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.